Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: Findings from an open-label treatment extension

Nicolino Ruperto, Daniel J. Lovell, Ruben Cuttica, Patricia Woo, Silvia Meiorin, Carine Wouters, Earl D. Silverman, Zsolt Balogh, Michael Henrickson, Joyce Davidson, Ivan Foeldvari, Lisa Imundo, Gabriele Simonini, Joachim Oppermann, Stephen Xu, Yaung Kaung Shen, Sudha Visvanathan, Adedigbo Fasanmade, Alan Mendelsohn, Alberto MartiniEdward H. Giannini

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Objective: To assess the long-term efficacy and safety of infliximab plus methotrexate in juvenile rheumatoid arthritis (JRA). Methods: Patients eligible for the open-label extension (OLE, weeks 52-204) received infliximab 3-6 mg/kg every 8 weeks plus methotrexate. Results: Of the 78/122 (64%) children entering the OLE, 42 discontinued infliximab, most commonly due to consent withdrawal (11 patients), lack of efficacy (eight patients) or patient/physician/sponsor requirement (eight patients). Infliximab (mean dose 4.4 mg/kg per infusion) was generally well tolerated. Infusion reactions occurred in 32% (25/78) of patients, with a higher incidence in patients positive for antibodies to infliximab (58%, 15/26). At week 204, the proportions of patients achieving ACR-Pedi-30/50/70/90 response criteria and inactive disease status were 44%, 40%, 33%, 24% and 13%, respectively. Conclusions: In the limited population of JRA patients remaining in the study at 4 years, infliximab was safe and effective but associated with a high patient discontinuation rate. Clinical trials registration number NCT00036374.

Original languageEnglish
Pages (from-to)718-722
Number of pages5
JournalAnnals of the rheumatic diseases
Volume69
Issue number4
DOIs
Publication statusPublished - Apr 1 2010

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: Findings from an open-label treatment extension'. Together they form a unique fingerprint.

  • Cite this

    Ruperto, N., Lovell, D. J., Cuttica, R., Woo, P., Meiorin, S., Wouters, C., Silverman, E. D., Balogh, Z., Henrickson, M., Davidson, J., Foeldvari, I., Imundo, L., Simonini, G., Oppermann, J., Xu, S., Shen, Y. K., Visvanathan, S., Fasanmade, A., Mendelsohn, A., ... Giannini, E. H. (2010). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: Findings from an open-label treatment extension. Annals of the rheumatic diseases, 69(4), 718-722. https://doi.org/10.1136/ard.2009.100354